CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that it
will be presenting updated progression-free survival and overall
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will be presenting updated progression-free survival and overall survival results from its completed Phase 1b/2 clinical trial of aldoxorubicin in soft tissue sarcoma. The trial was conducted at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial’s principal investigator, Dr. Sant Chawla, will present the data at CytRx’s Research and Development Day which is taking place on Friday, May 2, from 8:30 – 11:30 am EDT at the Harvard Club in New York City. In results for the study previously reported at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2012, partial responses were observed in 5 of 13 patients with metastatic soft tissue sarcomas who had progressed following initial chemotherapy. Eight of 13 patients showed evidence of tumor shrinkage; 5 of these 8 patients had received prior doxorubicin chemotherapy and had not demonstrated tumor reduction. Patients were followed until disease progression, death or withdrawal of consent. Aldoxorubicin is currently being studied in a pivotal global Phase 3 clinical trial evaluating the efficacy and safety of aldoxorubicin as a second-line treatment for patients with STS under a Special Protocol Assessment with the FDA. CytRx is also conducting two Phase 2 clinical trials evaluating aldoxorubicin in patients with late-stage glioblastoma (GBM) and HIV-related Kaposi’s sarcoma. The Research and Development Day, which will be open to analysts and institutional investors, will include presentations by, and a panel discussion with, key opinion leaders in oncology and sarcoma, including the principal investigator for the Company’s pivotal, global Phase 3 trial of aldoxorubicin in patients with soft tissue sarcoma. CytRx invites the public and the media to join the event via the webcast. Please RSVP to email@example.com. A webcast of the presentation can be accessed at the following link: http://wsw.com/webcast/cc/cytr/register.aspx?conf=cc&page=cytr&url=http%3A//wsw.com/webcast/cc/cytr/ A replay of the webcast will also be archived on the Investor Relations section of the CytRx website following the event.